Date: 2013-06-27
Type of information: Collaboration agreement
Compound:
Company: Karolinska Development (Sweden) Ospedale San Raffaele (Italy) Medical University of Graz (Austria)
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On June 27, 2013, Karolinska Development has announced that it has teamed up with two more world class research centers. Deal flow agreements have been signed with the Italian university hospital Ospedale San Raffaele and the Medical University of Graz in Austria, which enable Karolinska Development to identify investment opportunities among life science innovations emanating from these leading medical research institutions. Karolinska Development will assist in the evaluation and assessment of new innovations from each institution, and has the opportunity to invest in commercially attractive projects. The institutions will benefit from Karolinska Development’s drug and device development expertise and will be offered engagement in any companies created from the collaborations. Similar deal flow agreements are already established with, among others, Karolinska Institutet in Sweden and Mayo Clinic in the US.
Ospedale San Raffaele is one of the leading research institutions in Europe. The Italian university hospital is the highest ranking Italian biomedical research institute with about 760 research scientists and 680 clinical researchers working at translational programs, engaged in basic and clinical research within gene therapy, stem cells, immunology, neurodegenerative diseases, proteomics, bioinformatics, neurobiology, molecular biology and diabetes. In 2012, Ospedale San Raffaele was involved in more than 700 clinical studies including about 9,500 patients.
The Medical University of Graz is conducting training, education and research at world-class level, focusing on continuous improvement of top quality medicine and surgery.
Financial terms:
Latest news:
